Heba Youssef: Anticoagulation Bridging – A Clinical Summary Every Practitioner Should Know
Heba Youssef, Clinical Nutrition Pharmacist at Helwan General Hospital, shared a post on LinkedIn:
“Anticoagulation Bridging:
A Clinical Summary Every Practitioner Should Know
Navigating perioperative anticoagulation decisions can be complex — but getting it right is critical for patient safety.
Here are the key clinical pearls from the latest evidence and CHEST 2022 Guidelines:
Why Bridging Therapy Exists?
When initiating warfarin, Protein C drops rapidly while Prothrombin (Factor II) persists for 42–72 hours — creating a transient ‘hypercoagulable‘ window.
Overlapping with UFH or LMWH for a minimum of 5 days bridges this gap safely.
The 5-Day Rule
Stop heparin/LMWH ‘only’ when BOTH conditions are met:
- INR ≥ 2.0
- INR therapeutic for ≥ 24 hours (or two consecutive therapeutic readings)
Routine Perioperative Bridging? Not Recommended.
CHEST 2022 states routine heparin bridging is generally Not recommended for most patients — increased bleeding risk with little to no reduction in thromboembolism.
Reserve it for selected high-risk cases: mechanical heart valves, recent VTE < 3 months, or recent arterial thromboembolism.
DOACs: No Bridging Needed.
Their short half-life and rapid onset make perioperative bridging unnecessary.
Always Watch for HIT.
Platelet drop > 50%, typically 5–10 days post-exposure? Suspect Heparin-Induced Thrombocytopenia.
Stop all heparin immediately and switch to a non-heparin anticoagulant (Argatroban, Fondaparinux, or Bivalirudin).
Reversal When It Matters.
- UFH reversal with Protamine Sulfate
- Life-threatening warfarin bleeding reversal with 4-Factor PCC and IV Vitamin K (faster and more sustained than FFP)
Sound anticoagulation management is where pharmacology, clinical judgment, and patient safety converge.
These principles save lives when applied correctly.
What aspect of anticoagulation bridging do you find most challenging in clinical practice? ”
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 11:46Madiha Chowdhury: Behind the Scenes of Blood Transfusion Services
-
Nov 16, 2026, 11:43Nasir Al Allawi: Honouring Excellence in Haematopathology
-
Nov 16, 2026, 11:39Osman El-Maarri: Delete Two Genes from a Cell Line and It Secretes Twice as much Factor VIII
-
Nov 16, 2026, 11:37Chaza Alaji: Unexplained Bruising-Beyond Platelet Counts and Coagulation Tests
-
Nov 16, 2026, 11:33Obed Asumadu: How Can Advanced Laboratory Diagnostics Improve the Detection and Management of Haemophilia?
-
Nov 16, 2026, 11:29Amman Yousaf: Pulmonary Embolism Mortality in Patients With Coagulation Disorders at AHA 2026
-
Nov 16, 2026, 10:48Tareq Abadl: Why the Kell Blood Group System Matters
-
Nov 16, 2026, 10:40TIF in China – Advancing Regional Cooperation in Thalassaemia Prevention and Care
-
Nov 16, 2026, 10:40Dhargam Aljebouri: A Milestone for Transfusion Medicine in Iraq